| Name | Title | Contact Details |
|---|
At South Carolina Federal Credit Union, we connect remarkable people with exceptional opportunities. We are passionate about exceeding expectations and providing "Life Simplified" experiences for our members, and were are proud to be an Employer of Choice organization where people matter. Weve been selected 11 times as one of the Best Places to Work in SC, six times as one of the Best Credit Unions to Work For nationally, and were currently on Glassdoors coveted Best Places to Work list for the fifth time. Our core values of honesty, teamwork, professionalism, positivity, and accountability, coupled with our ability to share the vision, help us to stand out as leaders within the financial services industry. We offer a full range of financial services, including savings and investments, checking, credit cards, and loans. We offer a personable environment, with convenience unsurpassed in our area. Credit union membership is ownership. We are not-for-profit and exist only for the financial benefit of our members. As a result, South Carolina Federal is able to pay competitive dividends on savings and offer attractive interest rates on loans. We invite you to visit our website to learn more... www.scfederal.org.
HBT is a not-for-profit health and welfare trust that provides group health and welfare benefits on behalf of participating employers for nearly 265,000 eligible employees, their eligible dependents, and beneficiaries employed in health care and social services in British Columbia. The primary benefits provided by HBT are Group Life, Accidental Death & Dismemberment (AD&D), Weekly Indemnity, Long Term Disability (LTD), Extended Health, and Dental. HBT ensures these benefits are administered in accordance with provisions and plan design negotiated by HEABC, CSSEA, and single-site collective agreements.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.